跳至主要内容
临床试验/NCT05100836
NCT05100836已完成不适用

SURPASS Study - The Surgical Unloading Renal Protection And Sustainable Support Study

Abiomed Inc.15 个研究点 分布在 1 个国家目标入组 1,017 人开始时间: 2020年9月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Abiomed Inc.
入组人数
1,017
试验地点
15
主要终点
Survival Outcome

研究概览

简要总结

A multi-center, prospective & retrospective, observational single-arm study of the clinical outcomes up to one year collected from electronic health records of patients which have undergone standard of care implantation of Impella 5.5, regardless of clinical situation or indication. All patients will be enrolled via an IRB-approved Waiver of Informed Consent and HIPAA Authorization.

All patients who were supported retrospectively (prior to site IRB approval) with Impella 5.5 at the investigative site will be entered into the SURPASS registry and specified as the retrospective cohort.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Subject has previously undergone an Impella 5.5 implant at a study site

排除标准

  • Patients not receiving Impella 5.5

结局指标

主要结局

Survival Outcome

时间窗: One year

The rate of patients who survived at Impella 5.5 explant, hospital discharge and follow-up up to 1 year

次要结局

未报告次要终点

研究者

发起方
Abiomed Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (15)

Loading locations...

相似试验